137 related articles for article (PubMed ID: 1409308)
21. Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression.
Du XF; Jiang CZ; Wu CF; Won EK; Choung SY
Arch Pharm Res; 2008 Sep; 31(9):1153-9. PubMed ID: 18806958
[TBL] [Abstract][Full Text] [Related]
22. [Levels of interleukin-2 )IL-2 and tumor necrosis factor alpha (TNF-alpha) mRNA in aged rat spleen under physiological conditions and in septic shock: possible role of pidotimod in gene expression modulation].
Arosio B; Santambrogio D; Gagliano N; Annoni G
Drugs Exp Clin Res; 1993; 19 Suppl():9-14. PubMed ID: 8625783
[No Abstract] [Full Text] [Related]
23. Ex vivo evaluation of pidotimod activity in patients with chronic obstructive pulmonary disease.
Benetti GP; Illeni MT; Passera A; Bombelli G; Lavecchia G; Uslenghi C
Arzneimittelforschung; 1994 Dec; 44(12A):1503-5. PubMed ID: 7857352
[TBL] [Abstract][Full Text] [Related]
24. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice.
Taramelli D; Malabarba MG; Basilico N; Sala G; Mattina R; Cocuzza C
Arzneimittelforschung; 1994 Dec; 44(12A):1425-30. PubMed ID: 7857336
[TBL] [Abstract][Full Text] [Related]
25. Immunopharmacology of Pidotimod: effect on natural killer cell activity and thymocyte cell death.
Migliorati G; Coppi G; D'Adamio F; Pagliacci C; Nicoletti I; Riccardi C
Pharmacol Res; 1992 Sep; 26 Suppl 2():154-5. PubMed ID: 1409289
[No Abstract] [Full Text] [Related]
26. In vivo antiviral effects of pidotimod.
Dianzani C; Colangelo D; Tonso E; Guidotto S; Viano I
Arzneimittelforschung; 1994 Dec; 44(12A):1431-3. PubMed ID: 7857337
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children.
Caramia G; Clemente E; Solli R; Mei V; Cera R; Carnelli V; Venturoli V; Corsini A
Arzneimittelforschung; 1994 Dec; 44(12A):1480-4. PubMed ID: 7857347
[TBL] [Abstract][Full Text] [Related]
28. Pidotimod in allergic diseases.
Manti S; Parisi GF; Papale M; Leonardi S
Minerva Pediatr; 2020 Oct; 72(5):358-363. PubMed ID: 32731733
[TBL] [Abstract][Full Text] [Related]
29. Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator Pidotimod.
di Marco R; Condorelli F; Girardello R; Uslenghi C; Chisari G; di Mauro M; Speciale AM; Meroni PL; Nicoletti F
Scand J Infect Dis; 1992; 24(6):821-3. PubMed ID: 1287821
[TBL] [Abstract][Full Text] [Related]
30. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children.
Gourgiotis D; Papadopoulos NG; Bossios A; Zamanis P; Saxoni-Papageorgiou P
J Asthma; 2004; 41(3):285-7. PubMed ID: 15260461
[TBL] [Abstract][Full Text] [Related]
31. Pidotimod enhanced the anti-growth effect of cisplatin on lung cancer in mice via promoting anti-tumor immune response.
Wu T; Cui J; Gao J; Zhou H; Li A; Guo W
Biochem Biophys Res Commun; 2020 Aug; 528(4):678-684. PubMed ID: 32513535
[TBL] [Abstract][Full Text] [Related]
32. Synergistic immunostimulatory effect of pidotimod and red ginseng acidic polysaccharide on humoral immunity of immunosuppressed mice.
Du Xiao F; Jiang CZ; Wu CF; Won EK; Choung SY
Pharmazie; 2008 Dec; 63(12):904-8. PubMed ID: 19177908
[TBL] [Abstract][Full Text] [Related]
33. Pidotimod in the management of vulvar papillomatosis: double-blind clinical trial versus placebo.
Guerra B; Perino A; Polatti F; Scala M
Am J Ther; 1998 May; 5(3):147-52. PubMed ID: 10099052
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome.
La Mantia I; Grillo C; Mattina T; Zaccone P; Xiang M; Di Mauro M; Meroni PL; Nicoletti F
J Chemother; 1999 Apr; 11(2):126-30. PubMed ID: 10326743
[TBL] [Abstract][Full Text] [Related]
35. Pidotimod activity against chronic bronchitis exacerbations.
Ciaccia A
Arzneimittelforschung; 1994 Dec; 44(12A):1516-20. PubMed ID: 7857355
[TBL] [Abstract][Full Text] [Related]
36. General pharmacology of pidotimod and testing for drug interactions.
Manzardo S; Falcone A; Pinzetta A; Ieva G; Coppi G
Arzneimittelforschung; 1994 Dec; 44(12A):1441-7. PubMed ID: 7857339
[TBL] [Abstract][Full Text] [Related]
37. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials.
Niu H; Wang R; Jia YT; Cai Y
Int Immunopharmacol; 2019 Feb; 67():35-45. PubMed ID: 30530167
[TBL] [Abstract][Full Text] [Related]
38. Pidotimod in the management of recurrent pharyngotonsillar infections in childhood.
Passali D; Calearo C; Conticello S
Arzneimittelforschung; 1994 Dec; 44(12A):1511-6. PubMed ID: 7857354
[TBL] [Abstract][Full Text] [Related]
39. Protective effects of pidotimod against experimental bacterial infections in mice.
Coppi G; Falcone A; Manzardo S
Arzneimittelforschung; 1994 Dec; 44(12A):1417-21. PubMed ID: 7857334
[TBL] [Abstract][Full Text] [Related]
40. Gene expression for interleukin-2 and tumor necrosis factor-alpha in the spleen of old rats under physiological condition and during septic shock. Possible pharmacological modulation.
Annoni G; Arosio B; Santambrogio D; Cullurà D; Gagliano N; Uslenghi C
Arzneimittelforschung; 1994 Dec; 44(12A):1433-6. PubMed ID: 7531977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
